Intensity Therapeutics, Inc. (NASDAQ: INTS) reported Q2 EPS of ($1.43), $1.03 worse than the analyst estimate of ($0.40).

For earnings history and earnings-related data on Intensity Therapeutics, Inc. (INTS) click here.